
Seres Therapeutics (NASDAQ:MCRB) brought in sales totaling $7.22 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 173.3%, resulting in a loss of $50.00 million. Seres Therapeutics reached earnings of $68.22 million and sales of $126.72 million in Q3.